Head and Neck Squamous-Cell Carcinoma. Malignant neoplasm of connective and soft tissue of head, face and neck
Conditions
Interventions
The intervention group was supplemented with vitamin D (manufactured by Ariafarmed Peshgaman Salamat Pharmaceutical Company) at a dose of 2000 units per day and the control group (second) received pla
Sponsors
Kerman University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients with histopathologically proven head and neck squamous cell carcinoma Age 20 to 75 years
Exclusion criteria
Exclusion criteria: Previous use of vitamin D supplements History of previous chemoradiotherapy Allergy to vitamin D supplements The presence of metastasis Failure to complete the standard treatment protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor recurrence through clinical examination and imaging: Tumor recurrence in the primary site of the tumor underwent surgery, tumor recurrence in a place other than the primary tumor site, such as the involvement of other organs than the head and neck. Timepoint: 1.5 years. Method of measurement: Clinical examination or imaging if necessary. | — |
Secondary
| Measure | Time frame |
|---|---|
| Response to chemoradiotherapy by clinical examination and imaging: tumor volume reduced by less than 50% of the initial amount: no response, tumor volume reduced by more than 50% of the initial amount: partial response, no residual tumor: complete answer. Timepoint: 1.5 year. Method of measurement: Clinical examination or imaging if necessary. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNiloofar Mohammadi
Kerman University of Medical Sciences
Outcome results
None listed